Bristol-Myers Squibb Company
METHODS OF USING CTLA4Ig SUBCUTANEOUS FORMULATIONS
Last updated:
Abstract:
The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.
Status:
Application
Type:
Utility
Filling date:
24 Mar 2020
Issue date:
23 Jul 2020